The Australian stem cell biotech Mesoblast (MSB) has reportedly reached a deal with the American stem cell biotech Osiris (OSIR) to buy Osiris’ mesenchymal stem cell (MSC) unit. This is a big development in the MSC field. Osiris and Mesoblast are two major players in this particular subfield of the stem cell world so this deal, …
Mesoblast (MSB) buys Osiris (OSIR) stem cell unit Read More »
Over at the Harvard Law “Bill of Health” blog, Mary Ann Chirba and Alice A. Nobel posted a piece entitled “Our Bodies, Our Cells” a few days ago that has generated a lot of discussion about FDA regulation of stem cell interventions. Their piece really has two parts. In the first part they go through …
My response to ‘Our Bodies, Our Cells’ Harvard post on deregulation Read More »
Today’s post is an interview I did with Dr. Van Bokkelen covering 10 questions. Dr. Gil Van Bokkelen is Chairman and CEO of Athersys, Inc., a company that has focused heavily on stem cells and regenerative medicine for more than a decade. For more on Dr. Van Bokkelen’s background see additional bio section at the end of …
I’ve been fortunate to interview some of the greats in the stem cell field for this blog and host debates between key players. Please note that just because I have interviewed folks does not mean I agree with them or that they agree with me. The point is to establish dialogue on key issues. As …